TGF-beta (Transforming Growth Factor beta) Antibody - Without BSA and Azide
Mouse Monoclonal Antibody [Clone 1D11.16.8 ]
|Other Accession||7040 (beta1), 7042 (beta2), 7043 (beta3), 645227, P10600 (beta2), P61812 (beta3)|
|Reactivity||Human, Mouse, Hamster, Monkey, Cow, Dog|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Transforming growth factor beta-1, TGF-beta-1, Latency-associated peptide, LAP, TGFB1, TGFB|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||TGF-beta (Transforming Growth Factor beta) Antibody - Without BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts (By similarity). Stimulates sustained production of collagen through the activation of CREB3L1 by regulated intramembrane proteolysis (RIP) (PubMed:25310401). Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development. At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells. Mediates SMAD2/3 activation by inducing its phosphorylation and subsequent translocation to the nucleus (PubMed:25893292). Can induce epithelial-to-mesenchymal transition (EMT) and cell migration in various cell types (PubMed:25893292).|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
|Tissue Location||Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Colocalizes with ASPN in chondrocytes within OA lesions of articular cartilage.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This MAb recognizes TGF beta 1, 2 and 3. Three TGFĪ �s have been identified in mammals. TGFĪ �1, TGFĪ �2 and TGFĪ �3 are each synthesized as precursor proteins that are very similar in that each is cleaved to yield a 112 amino acid polypeptide that remains associated with the latent portion of the molecules. Biologically active TGFĪ � requires dimerization of the monomers (usually homodimers) and release of the latent peptide portion. Overall, the mature region of the TGFĪ �3 protein has approximately 80% identity to the mature region of both TGFĪ �1 and TGFĪ �2. However, the NH2 terminals or precursor regions of their molecules share only 27% sequence identity. TGFĪ �ā€™s inhibit the growth of epithelial cells and stimulate the growth of mesenchymal cells.Ā
Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol. 1989 Mar 1;142(5):1536-41
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.